Aneela Munir
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Aneela Munir has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Ghulam Ayesha Javed
University of the Punjab, Lahore 54590, Pakistan
2 shared publications - Najma Arshad
Institute of Zoology, University of the Punjab, Lahore, Pakistan
2 shared publications - Saman Javed
University of the Punjab, Lahore 54590, Pakistan
2 shared publications - Hafiza Samra Ambreen
University of the Punjab, Pakistan
1 shared publication - Kiran Shazadi
University of the Punjab, Pakistan
1 shared publication
Latest Publications
- 28 July 2023
- Published by Elsevier in Process Biochemistry
- Vol. 133, 11-19
Weissella confusa MW051433 and Levilactobacillus brevis MW362788 of human milk origin possess antioxidant competency: In vivo evidence
- 28 July 2023
- Published by Elsevier in Process Biochemistry
- Vol. 133, 11-19
Weissella confusa MW051433 and Levilactobacillus brevis MW362788 of human milk origin possess antioxidant competency: In vivo evidence
- 1 September 2022
- Published by Oxford University Press (OUP) in Journal of Applied Microbiology
- Vol. 133 (3) , 1725-1742
Levilactobacillus brevis from carnivores can ameliorate hypercholesterolemia: In vitro and in vivo mechanistic evidence
Aims: The aim was to explore the probiotic and hypocholesterolaemic potential of two Levilactobacillus brevis strains of carnivore origin along with selected underlying mechanisms. Methods and Results: Levilactobacillus brevis MT950194 and L. brevis MW365351 were analysed in vitro for oro-gastro-intestinal stress tolerance, cholesterol reduction, cholesterol adsorption (through scanning electron microscopy) and bile salt hydrolase (BSH) activity. Strains could survive (>80%) in oro-gastro-intestinal conditions and reduce high amount of cholesterol (35% and 54%) from media containing bile salts (0.3%) as compared with Lactobacillus acidophilus ATCC 4356 and presented the least pathogenicity towards mammalian cells. Exopolysaccharide production, cell surface cholesterol adherence and BSH activity were witnessed as possible cholesterol-lowering mechanisms. In in vivo experiment, the treatments of hypercholesterolaemic rats with L. brevis MT950194, L. brevis MW365351 and their mixture led to significant (p < 0.05) reduction in serum and hepatic cholesterol, low-density lipids, cholesterol ratio, liver steatosis and size of adipocytes. It further ameliorated diet-induced changes in hepatic enzymes. Conclusions: Levilactobacillus brevis MT950194 and L. brevis MW365351 from carnivores have probiotic pharmacological potential and can reduce serum cholesterol through surface adherence and BSH production. Significance and Impact of the Study: These strains may be utilized in treating hypercholesterolaemia and production of low-fat functional foods.
- 1 September 2022
- Published by Oxford University Press (OUP) in Journal of Applied Microbiology
- Vol. 133 (3) , 1725-1742
Levilactobacillus brevis from carnivores can ameliorate hypercholesterolemia: In vitro and in vivo mechanistic evidence
Aims: The aim was to explore the probiotic and hypocholesterolaemic potential of two Levilactobacillus brevis strains of carnivore origin along with selected underlying mechanisms. Methods and Results: Levilactobacillus brevis MT950194 and L. brevis MW365351 were analysed in vitro for oro-gastro-intestinal stress tolerance, cholesterol reduction, cholesterol adsorption (through scanning electron microscopy) and bile salt hydrolase (BSH) activity. Strains could survive (>80%) in oro-gastro-intestinal conditions and reduce high amount of cholesterol (35% and 54%) from media containing bile salts (0.3%) as compared with Lactobacillus acidophilus ATCC 4356 and presented the least pathogenicity towards mammalian cells. Exopolysaccharide production, cell surface cholesterol adherence and BSH activity were witnessed as possible cholesterol-lowering mechanisms. In in vivo experiment, the treatments of hypercholesterolaemic rats with L. brevis MT950194, L. brevis MW365351 and their mixture led to significant (p < 0.05) reduction in serum and hepatic cholesterol, low-density lipids, cholesterol ratio, liver steatosis and size of adipocytes. It further ameliorated diet-induced changes in hepatic enzymes. Conclusions: Levilactobacillus brevis MT950194 and L. brevis MW365351 from carnivores have probiotic pharmacological potential and can reduce serum cholesterol through surface adherence and BSH production. Significance and Impact of the Study: These strains may be utilized in treating hypercholesterolaemia and production of low-fat functional foods.